The filing shows continued cash burn and reliance on ATM dilution for funding. With only $6.1M cash and no near-term revenue catalyst, the company will likely need additional financing within 12 months. Preclinical data for IM1240 is early-stage and does not change the fundamental cash runway concern. Monitor for partnership announcements or further equity raises.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 7 $1.43entry
- T+1 · 3mo ago +4.90%α +4.92% · $1.50
- T+5 · 3mo ago +4.90%α +4.50% · $1.50
- T+20 · 2mo ago +22.38%α +22.77% · $1.75
- T+60 · 15d ago −14.69%α −12.55% · $1.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Purple Biotech reported Q2 2026 financial results with a net income of $0.4M driven by non-cash warrant revaluation gains, while operating loss widened to $1.3M. Cash and equivalents stood at $6.1M, providing runway through mid-2027 per management. Preclinical data for lead candidate IM1240 was presented at EACR 2026, supporting its safety and pharmacokinetic profile, but the program remains pre-clinical with clinical entry targeted for 2027. The company raised $2.3M gross via an ATM program during H1 2026, adding dilution.
Key Facts
- Cash and cash equivalents + short-term deposits totaled $6.1M as of June 30, 2026, down from $9.6M at Dec 31, 2025.
- Net cash used in operating activities was $5.6M for H1 2026 vs $3.5M in H1 2025.
- Operating loss for Q2 2026 was $1.3M, up from $1.2M in Q2 2025.
- Net income of $0.4M in Q2 2026 was entirely due to a $1.7M non-cash gain from warrant revaluation.
- Adjusted net loss (ex-warrant revaluation and stock comp) was $1.2M in Q2 2026 vs $1.1M in Q2 2025.
- Issued 692k ADS under ATM program in H1 2026, raising $2.3M gross ($2.0M net).
- IM1240 tri-specific antibody preclinical data presented at EACR 2026; clinical studies targeted for 2027.
- Accumulated loss reached $170.7M; total equity was $12.2M.
- Warrant liability fell from $4.1M at Dec 31, 2025 to $0.2M at June 30, 2026 due to revaluation.
- Company has no revenue and relies on financing for operations.
Financial Impact
Cash burn rate of ~$1.0M/month (operating cash outflow $5.6M over 6 months); $6.1M cash provides ~12 months runway at current burn. Dilution from ATM: 692k ADS issued, representing ~43% of opening ADS count (930k).
Risk Factors
- Cash runway only through mid-2027; may require dilutive financing before then.
- No approved products or revenue; clinical development of IM1240 is years away from potential commercialization.
- Significant dilution from ATM program (692k ADS in H1 2026 vs 930k opening balance).
- Geopolitical risk from Israel operations amid regional conflict.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-086393 |
| Document: ea030094001ex99-1.htm | 0001213900-26-086393 |
| Document: ea0300940-6k_purple.htm | 0001213900-26-086393 |
| Document: 0001213900-26-086393-index-headers.html | 0001213900-26-086393 |
| Document: 0001213900-26-086393-index.html | 0001213900-26-086393 |
| Document: 0001213900-26-086393.txt | 0001213900-26-086393 |
Track record
14 reports on PPBT
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago SC 13G Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
- Nov 12, 20265d ago EFFECT Neutral 3/10 Entry $1.56 Now $1.68 +7.69% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $1.49 Now $1.68 +12.75% settles Feb 9
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $1.09 Now $1.68 +54.13% settles Jan 27
- Oct 5, 20266w ago 6-K Neutral 2/10 Entry $1.47 Now $1.68 +14.29% settles Dec 31
- Sep 9, 20269w ago 6-K Neutral 2/10 Entry $1.74 Now $1.68 −3.45% settles Dec 4
- Sep 2, 202610w ago 6-K Neutral 3/10 Entry $1.98 Now $1.68 −15.15% settles Nov 27
- Aug 10, 202614w ago 6-K Neutral 4/10 Entry $1.55 to $1.22 Now $1.68 +8.39% ▼ −21.61% −21.13% vs SPY
- Aug 7, 202614w ago 6-K Neutral 4/10 Viewing Entry $1.43 to $1.22 Now $1.68 +17.48% ▼ −14.69% −12.55% vs SPY
- May 15, 202626w ago Press Release Neutral 4/10 Entry $3.94 to $1.55 Now $1.68 −57.36% ▼ −60.66% −65.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers